logo
Plus   Neg
Share
Email

Eli Lilly, Avidity Collaborate To Develop New Medicines In Immunology

Eli Lilly and Company (LLY) announced the company has expanded its oligonucleotide research and development strength through a collaboration with Avidity Biosciences, Inc. Avidity is a privately-held biotech company focused on Antibody Oligonucleotide Conjugates.

To utilize Avidity's technology platform, Eli Lilly will make an upfront payment of $20 million, as well as an investment of $15 million. Avidity is also eligible to receive up to approximately $405 million per target for various milestones, as well as tiered royalties.

Eli Lilly noted that there will be no change to the company's non-GAAP earnings per share guidance for the current year.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Alibaba is upgrading its intellectual property system using blockchain technology, according to local news outlet Sohu. Alibaba Platform Management expects this to benefit mainly small and medium-sized enterprises, brands and entrepreneurs. The technology will be fully implemented in September, and thereafter, the company intends to expand it to the field of digital copyright protection. Electronics retailer Best Buy Co., Inc. (BBY) reported Thursday a 27 percent increase in profit for the first quarter from last year, which was impacted by restructuring charges, and higher revenues. Both adjusted earnings per share and revenues for the quarter topped analysts' estimates. The company also provides guidance for the second quarter and reiterated its outlook for the full-year 2020. While reporting financial results for the second quarter on Thursday, Hormel Foods Corp. (HRL) lowered its earnings and net sales guidance for the full-year 2019. For fiscal 2019, the company now projects earnings in a range of $1.71 to $1.85 per share, and net sales between $9.70 billion and $10.20...
Follow RTT